Financials in USD. Standardized financial statements.
A compact view of how ANI Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $883.37M | $614.38M | $486.82M | $316.38M | $216.14M | $208.47M | $206.55M | $201.58M | $176.84M | $128.62M |
| Revenue Growth? | +43.8% | +26.2% | +53.9% | +46.4% | +3.7% | +0.9% | +2.5% | +14.0% | +37.5% | 0.0% |
| Cost of Revenue? | $432.73M | $250.21M | $181.51M | $138.78M | $100.61M | $87.16M | $63.15M | $73.02M | $79.03M | $48.78M |
| Gross Profit? | $450.64M | $364.17M | $305.30M | $177.60M | $115.53M | $121.32M | $143.39M | $128.55M | $97.81M | $79.84M |
| Gross Margin? | +51.0% | +59.3% | +62.7% | +56.1% | +53.5% | +58.2% | +69.4% | +63.8% | +55.3% | +62.1% |
| Operating Expenses? | $369.41M | $363.58M | $258.33M | $212.88M | $155.32M | $137.33M | $127.04M | $93.19M | $68.58M | $53.08M |
| Operating Income? | $81.23M | $584,000 | $46.97M | -$35.28M | -$39.79M | -$16.02M | $16.35M | $35.36M | $28.33M | $20.08M |
| EBITDA? | $207.27M | $63.12M | $106.60M | $25.04M | $3.12M | $28.13M | $60.73M | $69.10M | $57.16M | $56.31M |
| Income Before Tax | $95.79M | -$22.21M | $19.87M | -$62.66M | -$56.06M | -$25.96M | $3.16M | $20.05M | $16.35M | $8.68M |
| Income Tax Expense | $17.45M | -$3.69M | $1.09M | -$14.77M | -$13.46M | -$3.41M | -$2.94M | $4.56M | $17.43M | $4.74M |
| Net Income? | $78.34M | -$18.52M | $18.78M | -$47.90M | -$42.60M | -$22.55M | $6.09M | $15.49M | -$1.08M | $3.93M |
| EPS? | $3.50 | $-1.04 | $0.95 | $-3.05 | $-3.40 | $-1.88 | $0.51 | $1.33 | $-0.09 | $0.34 |
| Diluted EPS? | $3.32 | $-1.04 | $0.94 | $-3.05 | $-3.40 | $-1.88 | $0.50 | $1.32 | $-0.09 | $0.34 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality